Ambrx Biopharma (AMAM) Form 3 Initial statement of insider ownership

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

WuXi AppTec Co., Ltd.

(Last) (First) (Middle)

288 FUTE ZHONG ROAD

PUDONG NEW AREA

(Street)

SHANGHAI F4 200131

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2023

3. Issuer Name and Ticker or Trading Symbol
Ambrx Biopharma Inc. [ AMAM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	21,270,767	I	Held by WuXi PharmaTech Healthcare Fund I, L.P.(2)
Ordinary Shares(1)	7,996,920	I	Held by WuXi AppTec (Hong Kong) Holding Limited(3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

WuXi AppTec Co., Ltd.

(Last) (First) (Middle)

288 FUTE ZHONG ROAD

PUDONG NEW AREA

(Street)

SHANGHAI F4 200131

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

WuXi PharmaTech Healthcare Fund I L.P.

(Last) (First) (Middle)

288 FUTE ZHONG ROAD

PUDONG NEW AREA

(Street)

SHANGHAI F4 200131

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

WuXi AppTec (Hong Kong) Holding Ltd

(Last) (First) (Middle)

288 FUTE ZHONG ROAD

PUDONG NEW AREA

(Street)

SHANGHAI F4 200131

(City) (State) (Zip)

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer.

2. Shares are directly held by WuXi PharmaTech Healthcare Fund I, L.P. ("PharmaTech"). PharmaTech is an indirect, wholly owned subsidiary of WuXi AppTec Co., Ltd. ("AppTec Co"), which is the ultimate beneficial owner of PharmaTech and shares voting and investment authority over these shares.

3. Shares are directly held by WuXi AppTec (Hong Kong) Holding Limited ("AppTec HK"). AppTec HK is an indirect, wholly owned subsidiary of AppTec Co, which is the ultimate beneficial owner of AppTec HK and shares voting and investment authority over these shares.

Remarks:

	WuXi AppTec Co., Ltd., By: /s/ Edward Hu, Director	01/06/2023
	WuXi PharmaTech Healthcare Fund I, L.P., By: /s/ Edward Hu, Director	01/06/2023
	WuXi AppTec (Hong Kong) Holding Limited, By: /s/ Edward Hu, Director	01/06/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.